DK0474727T3
(da)
*
|
1989-05-19 |
1998-01-12 |
Genentech Inc |
HER2 ekstracellulært domæne
|
US5183884A
(en)
*
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US5578482A
(en)
*
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
US5776755A
(en)
*
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
US6107046A
(en)
*
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
US5811098A
(en)
*
|
1992-11-24 |
1998-09-22 |
Bristol-Myers Squibb Company |
Antibodies to HER4, human receptor tyrosine kinase
|
WO1995002057A1
(en)
*
|
1993-07-09 |
1995-01-19 |
The Institute Of Cancer Research |
Protein tyrosine kinase and ligands thereof
|
KR100355111B1
(ko)
*
|
1993-10-27 |
2003-03-03 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
발췌제거cDNA라이브러리제조법및제조된라이브러리의용도
|
US5518885A
(en)
*
|
1994-04-19 |
1996-05-21 |
The United States Of America As Represented By The Department Of Health & Human Services |
ERBB2 promoter binding protein in neoplastic disease
|
US7175995B1
(en)
|
1994-10-27 |
2007-02-13 |
Thomas Jefferson University |
TCL-1 protein and related methods
|
US5985598A
(en)
*
|
1994-10-27 |
1999-11-16 |
Thomas Jefferson University |
TCL-1 gene and protein and related methods and compositions
|
US5635351A
(en)
*
|
1995-03-14 |
1997-06-03 |
The Regents Of The University Of California |
Genetic gain and loss in gliomas
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
EP1728802A3
(de)
*
|
1996-03-27 |
2006-12-13 |
Genentech, Inc. |
ErbB3 Antikörper
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
JP4382879B2
(ja)
*
|
1996-07-12 |
2009-12-16 |
ジェネンテック・インコーポレーテッド |
ガンマ―ヘレグリン
|
JP4274581B2
(ja)
|
1996-07-12 |
2009-06-10 |
ジェネンテック・インコーポレーテッド |
キメラヘテロ多量体接着体
|
US5710137A
(en)
*
|
1996-08-16 |
1998-01-20 |
The Trustees Of Columbia University In The City Of New York |
Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6136558A
(en)
*
|
1997-02-10 |
2000-10-24 |
Genentech, Inc. |
Heregulin variants
|
CA2278151C
(en)
|
1997-02-10 |
2010-11-16 |
Genentech, Inc. |
Heregulin variants
|
WO1999021999A2
(en)
|
1997-10-29 |
1999-05-06 |
Genentech, Inc. |
Wnt-1 inducible genes
|
DE69834257T2
(de)
*
|
1997-04-30 |
2007-01-04 |
Klingemann, Hans |
Natürliche killerzelllinien und verfahren zu ihrer verwendung
|
US7052692B1
(en)
|
1997-09-02 |
2006-05-30 |
Advanced Research & Technology Institute |
Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
|
US6387657B1
(en)
|
1997-10-29 |
2002-05-14 |
Genentech, Inc. |
WISP polypeptides and nucleic acids encoding same
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20010023241A1
(en)
*
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
CN100340291C
(zh)
*
|
1998-10-09 |
2007-10-03 |
路德维格癌症研究院 |
F1t4(VEGFR-3)作为肿瘤显像和抗肿瘤治疗的靶
|
AU4209300A
(en)
*
|
1999-04-06 |
2000-10-23 |
Genentech Inc. |
Use of erbb receptor ligands in treating diabetes
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
EP1189634B1
(de)
*
|
1999-06-25 |
2007-02-28 |
Genentech, Inc. |
Behandlung von prostata-krebs mit anti-erbb2 antikörpern
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
DE60042693D1
(de)
|
1999-08-27 |
2009-09-17 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2-antikörpern
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US7390632B2
(en)
*
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
ES2331646T3
(es)
|
2000-05-19 |
2010-01-12 |
Genentech, Inc. |
Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
|
CN1204142C
(zh)
*
|
2000-06-01 |
2005-06-01 |
冯宝章 |
反基因V-erbB寡核苷酸及其应用
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
WO2002039121A2
(en)
*
|
2000-11-03 |
2002-05-16 |
Board Of Regents, The University Of Texas System |
Methods for detecting the efficacy of anticancer treatments
|
JP4669984B2
(ja)
|
2001-01-19 |
2011-04-13 |
ベジェニクス リミテッド |
腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法
|
EP1228766A1
(de)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion
|
AU2002257132A1
(en)
*
|
2001-04-06 |
2002-10-21 |
The Trustees Of The University Of Pennsylvania |
Erbb interface peptidomimetics and methods of use thereof
|
WO2002088363A2
(en)
*
|
2001-05-02 |
2002-11-07 |
Bayer Healthcare Ag |
Regulation of novel human prolyl 4-hydroxylases
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7638302B2
(en)
*
|
2001-05-31 |
2009-12-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
DE10131187C2
(de)
*
|
2001-06-28 |
2003-06-18 |
Infineon Technologies Ag |
Belichtungsmaske mit reparierter Blindstruktur
|
WO2003011897A1
(en)
*
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
EP1283053A1
(de)
*
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitore der HER3 Aktivität
|
AU2002326910A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Incyte Genomics, Inc. |
Receptors and membrane-associated proteins
|
JP2003110360A
(ja)
*
|
2001-09-28 |
2003-04-11 |
Seiko Epson Corp |
電圧制御型発振器、受信装置および通信装置
|
EP1495123B1
(de)
*
|
2002-03-26 |
2013-10-30 |
Zensun (Shanghai) Science and Technology Limited |
Auf erbb3 beruhende verfahren und zusammensetzungen zur behandlung von neoplasmen
|
US7402397B2
(en)
|
2002-05-21 |
2008-07-22 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
US20040229294A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
US20040229380A1
(en)
*
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
AU2003233662B2
(en)
|
2002-05-23 |
2010-04-01 |
Trustees Of The University Of Pennsylvania |
Fas peptide mimetics and uses thereof
|
RU2338751C2
(ru)
*
|
2002-07-15 |
2008-11-20 |
Дженентек, Инк. |
СПОСОБЫ ИДЕНТИФИКАЦИИ ОПУХОЛЕЙ, ВОСПРИИМЧИВЫХ К ЛЕЧЕНИЮ АНТИТЕЛАМИ ПРОТИВ ErbB2
|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
EP1572972A4
(de)
*
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
|
AU2004230700A1
(en)
|
2003-04-01 |
2004-10-28 |
Monogram Biosciences, Inc. |
Surface receptor complexes as biomarkers
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
CA2525969A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
US7402398B2
(en)
*
|
2003-07-17 |
2008-07-22 |
Monogram Biosciences, Inc. |
Measuring receptor homodimerization
|
WO2005019470A2
(en)
*
|
2003-08-11 |
2005-03-03 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
EP1681983A4
(de)
*
|
2003-10-14 |
2008-12-10 |
Monogram Biosciences Inc |
Rezeptor-tyrosin-kinase-signalpfad-analyse für diagnose und therapie
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005099756A2
(en)
*
|
2004-04-08 |
2005-10-27 |
Agus David B |
ErbB ANTAGONISTS FOR PAIN THERAPY
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
ES2521140T3
(es)
*
|
2004-07-22 |
2014-11-12 |
Genentech, Inc. |
Composición de anticuerpos de HER2
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7939267B2
(en)
*
|
2004-11-04 |
2011-05-10 |
Laboratory Corporation Of America Holdings |
Detection of activation of endothelial cells as surrogate marker for angiogenesis
|
KR20070085855A
(ko)
*
|
2004-12-07 |
2007-08-27 |
제넨테크, 인크. |
Her 억제제를 이용한 치료를 위한 환자 선택 방법
|
CN101141981A
(zh)
*
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
CN101115836A
(zh)
*
|
2005-02-09 |
2008-01-30 |
健泰科生物技术公司 |
用基质金属蛋白酶拮抗剂抑制her2脱落
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
LT2511301T
(lt)
|
2006-08-04 |
2018-04-10 |
Medimmune Limited |
Žmogaus antikūnas prieš erbb2
|
WO2008064884A1
(en)
*
|
2006-11-28 |
2008-06-05 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
KR101598229B1
(ko)
*
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Erbb3에 대한 항체 및 이의 용도
|
EP2132573B1
(de)
|
2007-03-02 |
2014-04-23 |
Genentech, Inc. |
Voraussage der reaktion auf einen her-dimerisationshemmer auf basis niedriger her3-expression
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
WO2009070772A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Monogram Biosciences, Inc. |
Enhanced method for detecting and/or quantifying an analyte in a sample
|
WO2009086197A1
(en)
*
|
2007-12-20 |
2009-07-09 |
Monogram Biosciences, Inc. |
Her-2 diagnostic methods
|
SG187490A1
(en)
*
|
2008-01-18 |
2013-02-28 |
Natco Pharma Ltd |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
EP2644204B1
(de)
|
2008-03-18 |
2017-04-19 |
Genentech, Inc. |
Kombination aus einem Anti-HER2-Antikörperwirkstoffkonjugat und Pertuzumab
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
WO2009157919A1
(en)
*
|
2008-06-23 |
2009-12-30 |
Tumor Biology Investment Group, Inc. |
SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER
|
KR20110044905A
(ko)
*
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
US20120295259A1
(en)
|
2011-05-19 |
2012-11-22 |
Laboratory Corporation Of America Holdings |
Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
|
US8349574B2
(en)
|
2009-01-15 |
2013-01-08 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of Her-3
|
US8470542B2
(en)
|
2008-12-01 |
2013-06-25 |
Laboratory Corporation Of America Holdings |
Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
|
TWI461211B
(zh)
*
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
JP2012525432A
(ja)
*
|
2009-04-29 |
2012-10-22 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
ヘレグリン共役型her3と免疫反応性の改善された抗体
|
WO2010132604A2
(en)
|
2009-05-13 |
2010-11-18 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
SG176073A1
(en)
|
2009-05-29 |
2011-12-29 |
Hoffmann La Roche |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
EP2488199A1
(de)
|
2009-10-14 |
2012-08-22 |
Merrimack Pharmaceuticals, Inc. |
Auf igf-1r- und erbb3-signalisierung gerichtete bispezfische bindemittel und ihre verwendung
|
PT2719708T
(pt)
*
|
2009-11-13 |
2018-01-16 |
Daiichi Sankyo Europe Gmbh |
Material e métodos para tratamento ou prevenção de doenças associadas a her-3
|
KR20120123299A
(ko)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
다중특이적 항체, 항체 유사체, 조성물 및 방법
|
RU2560583C2
(ru)
|
2009-12-22 |
2015-08-20 |
Рош Гликарт Аг |
Антитела к her3 и их применения
|
BR112012022802A2
(pt)
|
2010-03-11 |
2018-05-15 |
Merrimack Pharmaceuticals Inc |
uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
|
ES2566602T3
(es)
|
2010-04-09 |
2016-04-14 |
Aveo Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8741288B2
(en)
*
|
2010-07-07 |
2014-06-03 |
Chang Gung Medical Foundation, Linkou Branch |
Protein markers for detecting liver cancer and method for identifying the markers thereof
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CN103562226A
(zh)
|
2011-03-11 |
2014-02-05 |
梅里麦克制药股份有限公司 |
使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
|
MX336197B
(es)
|
2011-04-19 |
2016-01-11 |
Merrimack Pharmaceuticals Inc |
Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
|
PL2707391T3
(pl)
|
2011-05-13 |
2018-04-30 |
Gamamabs Pharma |
Przeciwciała przeciwko her3
|
EP2722343A4
(de)
|
2011-06-20 |
2014-12-17 |
Kyowa Hakko Kirin Co Ltd |
Anti-erbb3-antikörper
|
EP2736928B1
(de)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Gegen erbb3-gerichtete sur-bindende proteine
|
KR20140057356A
(ko)
|
2011-08-31 |
2014-05-12 |
제넨테크, 인크. |
진단 마커
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
US8791244B2
(en)
|
2011-09-30 |
2014-07-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies and uses thereof
|
CA2851314A1
(en)
|
2011-10-06 |
2013-04-11 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-erbb3 antibodies
|
UA123092C2
(uk)
|
2011-10-14 |
2021-02-17 |
Дженентек, Інк. |
Спосіб неоад'ювантного лікування her2-позитивного раку молочної залози на ранній стадії у пацієнта
|
EP2797957B1
(de)
|
2011-11-23 |
2019-06-19 |
MedImmune, LLC |
Her3-spezifische bindungsmoleküle und verwendungen davon
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
JP6243345B2
(ja)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
WO2013096828A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
CN108404129A
(zh)
|
2012-02-23 |
2018-08-17 |
第三共欧洲有限公司 |
用于调节放射敏感性的her3抑制剂
|
EP2831115A1
(de)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnose und behandlungen im zusammenhang mit her3-hemmern
|
AU2013243584A1
(en)
|
2012-04-02 |
2014-10-09 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-l1阻害剤併用療法を必要とする患者の同定
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
WO2014122582A1
(en)
|
2013-02-05 |
2014-08-14 |
Nestec S.A. |
Drug selection for non-small cell lung cancer therapy
|
US9745558B2
(en)
|
2013-02-18 |
2017-08-29 |
Vegenics Pty Limited |
VEGFR-3 ligand binding molecules and uses thereof
|
EP2981828A1
(de)
|
2013-04-05 |
2016-02-10 |
Laboratory Corporation of America Holdings |
Systeme und verfahren zur erleichterung der diagnose, prognose und behandlung von krebs auf basis der erkennung einer her3-aktivierung
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
MY195180A
(en)
|
2014-04-10 |
2023-01-11 |
U3 Pharma Gmbh |
Anti-HER3 Antibody-Drug Conjugate
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
CN107257691B
(zh)
|
2014-07-16 |
2021-09-21 |
达娜-法勃肿瘤研究所公司 |
低级别浆液性卵巢癌中的her3抑制
|
WO2016011343A1
(en)
|
2014-07-17 |
2016-01-21 |
The Trustees Of The University Of Pennsylvania |
Her3 peptides and dendritic cell vaccines
|
EP3229803B1
(de)
|
2014-12-12 |
2020-01-29 |
Massachusetts General Hospital |
Behandlung von brustkrebsgehirnmetastasen
|
WO2016196377A1
(en)
|
2015-05-29 |
2016-12-08 |
Merrimack Pharmaceuticals, Inc. |
Combination cancer therapies
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
WO2017002776A1
(ja)
|
2015-06-29 |
2017-01-05 |
第一三共株式会社 |
抗体-薬物コンジュゲートの選択的製造方法
|
EP3325005A4
(de)
*
|
2015-07-17 |
2019-03-27 |
Brian J. Czerniecki |
Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie
|
WO2017127545A1
(en)
|
2016-01-19 |
2017-07-27 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
|
US20190091227A1
(en)
|
2016-03-15 |
2019-03-28 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
KR20190095280A
(ko)
|
2016-12-12 |
2019-08-14 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
|
CA3046092A1
(en)
|
2016-12-28 |
2018-07-05 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
EP3572428A4
(de)
|
2017-01-17 |
2020-12-30 |
Daiichi Sankyo Company, Limited |
Anti-gpr20-antikörper und anti-gpr20-antikörper-arzneimittel-konjugat
|
UA123292C2
(uk)
|
2017-01-17 |
2021-03-10 |
Дженентек, Інк. |
Рідка фармацевтична композиція, яка містить пертузумаб та трастузумаб
|
US11077189B2
(en)
|
2017-03-02 |
2021-08-03 |
Genentech Inc. |
Adjuvant treatment of HER2-positive breast cancer
|
AU2018258263A1
(en)
|
2017-04-24 |
2019-10-24 |
Genentech, Inc. |
ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
AU2018275147B2
(en)
|
2017-06-02 |
2021-01-28 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
|
EP3677589A4
(de)
|
2017-08-31 |
2021-04-21 |
Daiichi Sankyo Company, Limited |
Verbessertes verfahren zur herstellung eines antikörper-wirkstoff-konjugats
|
JP7248578B2
(ja)
|
2017-08-31 |
2023-03-29 |
第一三共株式会社 |
抗体-薬物コンジュゲートの新規製造方法
|
EP4249002A3
(de)
|
2018-05-18 |
2023-11-22 |
Daiichi Sankyo Co., Ltd. |
Conjugue agent cytotoxique et anticorps anti-muc1-exatecan
|
IL299376A
(en)
|
2020-06-29 |
2023-02-01 |
Genentech Inc |
Fixed dose combination of pertuzumab plus transtuzumab
|
EP4180061A1
(de)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Linker-reagenzien für anthracyclinderivate, antikörper-arznemittelkonjugate und verfahren
|